Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Oct 14;23(4):414-417.
doi: 10.5935/1518-0557.20190045.

The impact of dehydroepiandrosterone in poor ovarian responders on assisted reproduction technology treatment

Cecilia de Souza Monteiro  1 , Bruno Brum Scheffer  1 , Rafaela Friche de Carvalho  1 , Juliano Brum Scheffer  1
Affiliations
Review

The impact of dehydroepiandrosterone in poor ovarian responders on assisted reproduction technology treatment

Cecilia de Souza Monteiro et al. JBRA Assist Reprod. .

Abstract

One in six couples worldwide will experience at least one infertility problem during their reproductive years. Between 5.6% and 35.1% of women will exhibit poor ovarian response. A variety of methods have been applied to improve ovarian response, including dehydroepiandrosterone. In the ovaries, dehydroepiandrosterone promotes follicular development and granulosa cell proliferation by increasing intraovarian androgen concentrations while simultaneously enhancing the level of follicular insulin-like growth factor-1, which promotes folliculogenesis. Dehydroepiandrosterone supplementation may improve in vitro fertilization outcomes and ovarian response in patients with poor ovarian response. However, a few questions still loom over the effectiveness of dehydroepiandrosterone.

Keywords: Bologna criteria; anti-Müllerian hormone; antral follicle count; dehydroepiandrosterone; in vitro fertilization; poor ovarian responder.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

The authors have no conflict of interest to declare.

References

    1. Barad D, Brill H, Gleicher N. Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function. J Assist Reprod Genet. 2007;24:629–634. doi: 10.1007/s10815-007-9178-x. - DOI - PMC - PubMed
    1. ESHRE . Press Information. ART fact sheet. 2018. https://www.eshre.eu/~/media/sitecore-files/Guidelines/ART-fact-sheet_vF...
    1. Ferrario M, Secomandi R, Cappato M, Galbignani E, Frigerio L, Arnoldi M, Fusi FM. Ovarian and adrenal androgens may be useful markers to predict oocyte competence and embryo development in older women. Gynecol Endocrinol. 2015;31:125–130. doi: 10.3109/09513590.2014.964639. - DOI - PubMed
    1. Fusi FM, Ferrario M, Bosisio C, Arnoldi M, Zanga L. DHEA supplementation positively affects spontaneous pregnancies in women with diminished ovarian function. Gynecol Endocrinol. 2013;29:940–943. doi: 10.3109/09513590.2013.819087. - DOI - PubMed
    1. González-Comadran M, Durán M, Solà I, Fábregues F, Carreras R, Checa MA. Effects of transdermal testosterone in poor responders undergoing IVF: systematic review and meta-analysis. Reprod Biomed Online. 2012;25:450–459. doi: 10.1016/j.rbmo.2012.07.011. - DOI - PubMed

Substances

LinkOut - more resources